company background image
TEVA

Teva Pharmaceutical Industries NYSE:TEVA Stock Report

Last Price

US$10.03

Market Cap

US$10.9b

7D

1.5%

1Y

16.4%

Updated

04 Dec, 2023

Data

Company Financials +

Teva Pharmaceutical Industries Limited

NYSE:TEVA Stock Report

Mkt Cap: US$10.9b

TEVA Stock Overview

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Teva Pharmaceutical Industries Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Teva Pharmaceutical Industries
Historical stock prices
Current Share PriceUS$10.03
52 Week HighUS$11.45
52 Week LowUS$7.09
Beta1.17
1 Month Change11.57%
3 Month Change4.92%
1 Year Change16.36%
3 Year Change-0.30%
5 Year Change-45.61%
Change since IPO1,237.33%

Recent News & Updates

Teva: Deeply Undervalued FCF Machine

Nov 20

Recent updates

Teva: Deeply Undervalued FCF Machine

Nov 20

Teva: Focus On Innovation And Growth Means The Times They Are A Changing

Sep 14

Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

Sep 09
Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

Aug 26

Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain

Aug 02

Teva Pharmaceutical: Lacking Capabilities For Strategic Investments

Jul 20

Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence

Jun 15

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Jun 06
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load

Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

Feb 20
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Feb 15

Can Teva Pharmaceutical's Q4 results bring positive surprise?

Feb 07

Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment

Jan 19

Tamiflu supplies released from national stockpile as nationwide shortage persists

Jan 12

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

Dec 28

Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex

Dec 16

Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit

Nov 10

Teva Pharmaceutical to pay New York $523M as part of opioid settlement

Nov 03

Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's

Oct 18

Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg

Oct 06

Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price

Sep 28

Teva Pharmaceutical: Past Behind And A Promising 2023

Sep 16

Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis

Aug 29

These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively

Aug 05
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively

Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg

Aug 03

Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings

Jul 26

Teva again in the sights of New York Attorney General over alleged role in opioid crisis

Jul 11

Teva names new medical chief

Jul 01

Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week

Jun 20

3 Reasons To Buy Teva At $10

Apr 07

Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?

Mar 24
Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?

Teva Pharmaceutical: Prepare For Takeoff

Feb 16

Teva: Competent Management Despite Lawsuits And Debts

Jan 28

Teva: Bracing For Next Catalyst

Dec 22

Teva: Definitely Undervalued

Dec 12

Teva Pharmaceutical Industries (NYSE:TEVA) Seems To Be Using A Lot Of Debt

Dec 07
Teva Pharmaceutical Industries (NYSE:TEVA) Seems To Be Using A Lot Of Debt

Five Considerations After Teva Pharmaceuticals' Q3 Report

Oct 31

Teva: Cautiously Bullish On 5-Year Prospects

Sep 17

The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value

Sep 17
The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value

Why Teva Pharmaceuticals Has Two A-Products In The Bag

Aug 10

Shareholder Returns

TEVAUS PharmaceuticalsUS Market
7D1.5%1.6%0.9%
1Y16.4%-3.0%13.6%

Return vs Industry: TEVA exceeded the US Pharmaceuticals industry which returned -3% over the past year.

Return vs Market: TEVA exceeded the US Market which returned 13.6% over the past year.

Price Volatility

Is TEVA's price volatile compared to industry and market?
TEVA volatility
TEVA Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: TEVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: TEVA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
190134,565Richard Francishttps://www.tevapharm.com

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.

Teva Pharmaceutical Industries Limited Fundamentals Summary

How do Teva Pharmaceutical Industries's earnings and revenue compare to its market cap?
TEVA fundamental statistics
Market CapUS$10.88b
Earnings (TTM)-US$2.21b
Revenue (TTM)US$15.27b

0.7x

P/S Ratio

-5.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TEVA income statement (TTM)
RevenueUS$15.27b
Cost of RevenueUS$8.27b
Gross ProfitUS$7.00b
Other ExpensesUS$9.21b
Earnings-US$2.21b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.97
Gross Margin45.84%
Net Profit Margin-14.46%
Debt/Equity Ratio265.9%

How did TEVA perform over the long term?

See historical performance and comparison